TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

News Analysis

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

The White House last week considered, but ultimately abandoned, a plan to create a panel that would review NIH grants in an effort to weed out projects the administration regards as “woke.”

HHS issues direct final rule to reduce reliance on animal testing

FDA has issued a direct final rule that changes the language in its regulations so that “animal testing” is no longer described as the default or defining form of “nonclinical” safety testing.

September 25, 2026

Vol.52 No.35

By Claire Marie Porter

In Brief

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.

September 18, 2026

Vol.52 No.34

In Brief

VCU Massey researchers receive $2.5M NIH grant for targeted therapy for breast, pancreatic cancer

Researchers at VCU Massey Comprehensive Cancer Center were recently awarded a $2.5 million R01 grant from NCI. The five-year grant will allow Massey to evaluate the efficacy of TROP2 targeted antibody-drug conjugates to further enhance therapeutic benefits in both breast and pancreatic cancer care.

September 18, 2026

Vol.52 No.34

Clinical Roundup

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

YOU MAY BE INTERESTED IN

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

HHS issues direct final rule to reduce reliance on animal testing

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

VCU Massey researchers receive $2.5M NIH grant for targeted therapy for breast, pancreatic cancer

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Renew today!

Subscriber content

Never miss an issue!

Login